论文部分内容阅读
体外试验曾揭示肿瘤患者的淋巴细胞能识别、杀伤自身肿瘤细胞。因此设想:在肿瘤局部分离出肿瘤特异性的淋巴细胞,并扩增此肿瘤反应性淋巴细胞群以杀灭此肿瘤。现已有实验证实肿瘤反应性T 细胞的存在,此种T 细胞最重要的特点是具有选择性。它对自身肿瘤的溶解,除了需识别MHC 抗原外,还需瘤细胞表达粘附分子ICAM-1,而抗原特异的细胞群的扩增则需要高亲合力的IL-2受体(IL-2R)的表达,同种异体抗原的刺激对T 细胞上的IL-2R 水平有正调节作用。本工作证实了淋巴细胞体外接触自身瘤细胞或同种异体淋巴细胞后,其细胞上
In vitro experiments have revealed that lymphocytes from cancer patients can recognize and kill their own tumor cells. Therefore, it is envisaged that tumor-specific lymphocytes are locally separated from the tumor and the tumor-reactive lymphocyte population is expanded to kill the tumor. Experiments have now confirmed the existence of tumor-reactive T cells, the most important feature of this T cell is selective. In addition to recognizing MHC antigens, tumor cells require tumor cells to express adhesion molecule ICAM-1, whereas antigen-specific cell population requires high affinity IL-2 receptor (IL-2R ), The stimulation of alloantigen has a positive effect on the level of IL-2R on T cells. This work confirmed that lymphocytes in vitro after contact with their own tumor cells or allogeneic lymphocytes, the cells